Fig. 3.

The therapeutic TNF-α blocking antibody Adalimumab down-modulates human T cell responses.

A) T cell stimulator cells expressing anti-CD3 antibodies at high levels (control) and T cell stimulator cells expressing anti-CD3 antibodies and human TNF-α were used to stimulate purified human T cells in the presence of control antibodies (control Ab) or the therapeutic anti-TNF-α antibody Adalimumab. B) T cell stimulator cells expressing the indicated costimulatory molecules were used to stimulate purified human T cells in the presence of control antibodies or Adalimumab (10 μg/ml). Data shown are representative for at least 5 independently performed experiments.